WSJ LIVE PORTFOLIO WSJ MARKETWATCH BARRON'S News, Quotes, Companies, Videos SEARCH ASIA EDITION U.S. EDITION Log In Subscribe PAID ADVISOR HOME MAGAZINE DAILY **INVESTING IDEAS TOP ADVISORS** MARKET DATA DIRECTORY

Xtandi Beats Casodex, Set to Top Zytiga

Medivation's prostate-cancer drug is generating strong data but the stock already reflects much of the potential.

Email	Print	0 Comments	Order Reprints	N
April 3, 2015				1

RBC Capital Markets

NVESTORS' SOAPBOX AM

As expected, Medivation's Xtandi handily beat AstraZeneca's Casodex in the STRIVE prostate-cancer study, too.

Median progression-free survival (PFS) of 19.4 for Medivation's (ticker: MDVN) Xtandi versus 5.7 months for AstraZeneca's (AZN) Casodex in the STRIVE study, versus 15.7 versus 5.8 months (Xtandi versus Casodex) in the TERRAIN study. The longer PFS in STRIVE versus TERRAIN is expected, given that STRIVE included both M0 and M1 (both nonmetastatic and metastatic) patients (396 patients, all U.S.), while TERRAIN included only M1 (metastatic castration-resistant prostate cancer (CRPC)) patients (375 patients in North America and Europe).

Median time on treatment was 14.7 versus 8.4 months for Xtandi versus Casodex, respectively, and 11.7 versus 5.8 months in TERRAIN. Adverse events (AEs) were reported in 29.4% versus 28.3% (Xtandi versus Casodex) in STRIVE, and 31.1% versus 23.3% in TERRAIN. G3 or higher cardiac AEs were 5.1% versus 4.0% (Xtandi versus Casodex), in line with 5.5% versus 2.1% in TERRAIN. There was one seizure in the Xtandi arm versus none in the Casodex arm, versus two for Xtandi and none for Casodex, in TERRAIN.

The data are positive and very consistent with the TERRAIN data and confirm the drug's good activity and safety. Seizures are still there, but one in about 200 patients in STRIVE and two in about 200 in TERRAIN, but this looks I ke an acceptable risk/benefit and physicians have already been comfortable with it. We believe these data will help the drug qet additional penetration in the pre-chemo setting, where we believe it will have the upper Iy due to convenience. However,

data, which will take many years to read out.

We believe Xtandi is a very active and well-tolerated agent that would have the upper hand in the pre-chemo setting given Zytiga's need for steroid use, so we project that Xtandi will eventually become the dominant player in these settings. However, given that Medivation shares this asset with Astellas Pharma [of Japan] (gets 50% of U.S. sales, low-teens to low-20s royalties outside the U.S.), and despite projecting very generous Xtandi sales (\$9 billion in 2026), we think Medivation shares already reflect the drug's potential and we would look for a better entry point into this story.

[We rate Medivation at Sector Perform.]

-- Simos Simeonidis

The opinions contained in Investors' Soapbox in no way represent those of Barrons.com or Dow Jones & Company, Inc. The opinions expressed are hose of the newsletter's writer(s) or analysts at research firms. Some of the research firms have provided, or hope to provide, investment-banking or other services to the companies being analyzed.


Most Popular

- 1. Bet on a Gilead Rally
- 2. Byron Wien Sees Global Dark Clouds Clearing
- 3. 6 Great Investors Explain What Makes Stocks Rise
- 4. What to Expect for Baidu, Alibaba, Tencent Earnings
- 5. SeaWorld Can Leap 30%

SEE FULL LIST

Latest Market Videos

1 The Cutting Edge in Private Jets



2 Apple Stock: Here's Why Earnings Disappointed



What Can Apple Do to Please Wall Street?



To be considered for the Spanhov feature, please submit an original article of less, han 1,000 words to



3 s of the disease will require Phase 3

Comme	ents? E-mai	l us at <u>editors(</u>	@barrons.com			
Email	Print	0 Comments	Order Reprints			
Lates	t in Investo	ors' Soapbo	x AM			
1.	StemCel	ls to Rebou	nd From Suit Disi			
 Sirius XM a Sole Sector Winner Citibank, Bank of New York Are Winners Best Home-Building Ideas Are Nuts and Bolts 						
5.	Semicon	ductors Sid	delined for the Sea			
			clude hometown for possible in	nclusion in Barron's magazine. Please	comply	
				Read Cor	nments	
		Want	to participate in the discussion	n?		
		Alroady a s	SUBSCRIBE NOW ▶ subscriber? Log In for complete			
CLEAR	POST					
						Return to Top
Custon	mer Service	Cre	eate an Account	About Barrons.com	Also From Barron's	Tools & Services
Custom	er Center	Sub	escribe to Barron's	Adverising	Conferences	Mobile Site
Contact Us			Magazine Subscribers: Ac ivate Your Digital Access	Mas head	Reprints	Email Newsletters
Live He	lp	7.0.	Nato Tour Digital Moocoo	Privacy Policy	Classifieds	Barron's on iPad/iPhone
				Cookie Policy	College Program	Barron's on Android
				Data Policy	Find a Broker	Portfolio
				Copyright Policy	Barron's in Japanese	Video
				Subscriber Agreement & Terms of Use		Annual Reports StockGrader
				Your Ad Choices		Barron's 400
				Community Guidelines		Economic Calendar
						Stock & Mutual Fund Listings
						Commodities, Op ions & Annui ies Lis ings
						Fund Prospectuses

Copyright ©2015 Dow Jones & Company, Inc. All Rights Reserved.

